LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Clarson, LE; Hider, SL; Belcher, J; Heneghan, C; Roddy, E; Mallen, CD (2014)
Publisher: BMJ
Journal: Annals of the Rheumatic Diseases
Languages: English
Types: Article
Subjects: Cardiovascular Disease, Epidemiology, Gout, 1507, Clinical and Epidemiological Research, 1506, R1
OBJECTIVES: To determine whether gout increases risk of incident coronary heart disease (CHD), cerebrovascular (CVD) and peripheral vascular disease (PVD) in a large cohort of primary care patients with gout, since there have been no such large studies in primary care. METHODS: A retrospective cohort study was performed using data from the Clinical Practice Research Datalink (CPRD). Risk of incident CHD, CVD and PVD was compared in 8386 patients with an incident diagnosis of gout, and 39 766 age, sex and registered general practice-matched controls, all aged over 50 years and with no prior vascular history, in the 10 years following incidence of gout, or matched index date (baseline). Multivariable Cox Regression was used to estimate HRs and covariates included sex and baseline measures of age, Body Mass Index, smoking, alcohol consumption, Charlson comorbidity index, history of hypertension, hyperlipidaemia, chronic kidney disease, statin use and aspirin use. RESULTS: Multivariable analysis showed men were at increased risk of any vascular event (HRs (95% CIs)) HR 1.06 (1.01 to 1.12), any CHD HR 1.08 (1.01 to 1.15) and PVD HR 1.18 (1.01 to 1.38), while women were at increased risk of any vascular event, HR 1.25 (1.15 to 1.35), any CHD HR 1.25 (1.12 to 1.39), and PVD 1.89 (1.50 to 2.38)) but not any CVD. CONCLUSIONS: In this cohort of over 50s with gout, female patients with gout were at greatest risk of incident vascular events, even after adjustment for vascular risk factors, despite a higher prevalence of both gout and vascular disease in men. Further research is required to establish the reason for this sex difference.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Kuo CF, Grainge MJ, Mallen CD, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74:661-7.
    • 2 Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007- 2008. Arthritis Rheum 2011;63:3136-41.
    • 3 Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010;62:170-80.
    • 4 Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885-92.
    • 5 Roddy E, Menon A, Hall A, et al. Polyarticular sonographic assessment of gout: a hospital-based cross-sectional study. Joint Bone Spine 2013;80:295-300.
    • 6 Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci 2012;17:656-69.
    • 7 Boogaerts MA, Hammerschmidt DE, Roelant C, et al. Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury. Thromb Haemost 1983;50:576-80.
    • 8 Chapman PT, Yarwood H, Harrison AA, et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997;40:955-65.
    • J Am Soc Nephrol 2005;16:3553-62.
    • Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988;41:237-42.
    • Krishnan E, Baker JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
    • Choi HK, Curhan G. Independent impact of gout on mortality and risk of coronary heart disease. Circulation 2007;116:894-900.
    • Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010;49:141-6.
    • Gelber AC, Klag MJ, Mead LA, et al. Gout and risk for subsequent coronary heart disease: the Meharry-Hopkins study. Arch Intern Med 1997;157:1436-40.
    • Janssens HJ, van de Lisdonk EH, Bor H, et al. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 2003;20:413-16.
    • Teng GG, Ang LW, Saag KG, et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 2012;71:924-8.
    • Angiology 2007;58:450-7.
    • Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology 2013;52:2251-9.
    • Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000;19:21-5.
    • Jordan K, Porcheret M, Kadam UT, et al. The use of general practice consultation databases in rheumatology research. Rheumatology 2006;45:126-8.
    • Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004;351:2611-18.
    • Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196-202.
    • Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
    • Tate AR, Beloff N, Al-Radwan B, et al. Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. J Am Med Inform Assoc 2014;21:292-8.
    • CPRD. http://www.cprd.com (last accessed 14 Jun 2014).
    • Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128-36.
    • Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14.
    • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
    • Khan NF, Perera R, Harper S, et al. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1.
    • Cox D. Regression Models and Life-Tables. J R Stat Soc Ser B Metho 1972;34:187-220.
    • Rogers W. Regression standard errors in clustered samples. Stata Tech Bull (sg17) 1993;13:19-23.
    • Bellera CA, MacGrogan G, Debled M, et al. Variables with time-varying effects and the Cox-model: Some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol 2010;10:20.
    • http://www.stata.com/manuals13/rlincom.pdf (accessed 11 July 2013).
    • Clarson L, Chandratre P, Hider S, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2013 Published Online First: 26 Nov 2013. doi: 10.1177/2047487313514895 DeVera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study.
    • Ann Rheum Dis 2010;69:1162-4.
    • Chen JH, Yeh WT, Chuang SY, et al. Gender-specific risk factors for incident gout: a prospective cohort study. Clin Rheumatol 2012;31:239-45.
    • Harrold LR, Yood RA, Mikuls TR, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 2006;65:1368-72.
    • Bhole V, de Vera M, Rahman MM, et al. Epidemiology of gout in women: fifty-two-year followup of a prospective cohort. Arthritis Rheum 2010;62:1069-76.
    • Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis 2010;69:1305-9.
    • BMC Cardiovasc Disord 2012;12:52.
    • Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007;3:229-34.
    • 44 45 Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66:1311-15.
    • Roddy E, Mallen CD, Hider SL, et al. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 2010;49:105-11.
    • Jordan KM, Cameron JS, Snaith M, et al.; on behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.
    • Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
    • Khanna D, Fitzgerald JD, Khanna PP, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1:systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46.
    • Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
    • Mikuls TR, Farrar JT, Bilker WB, et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005;44:1038-42.
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Cite this article